Name | Type | Posted | Actions |
|---|---|---|---|
Notice of Intent to Sole Source.pdf | May 19, 2026 |
Modification to the A11 HERV-E TCR and T cell product to improve the therapeutic efficacy for ccRCC patients.
Contact and place of performance
FALZONE, MICHAEL L
Bethesda, MD 20892
USA
Attachment: Notice of Intent to Sole Source
The National Institutes of Health, OLAO, issued this presolicitation notice regarding the modification of the A11 HERV-E TCR and T cell product. The primary purpose of this requirement is to improve therapeutic efficacy for clear cell renal cell carcinoma (ccRCC) patients. This procurement is identified under solicitation number 75N98026Q00392 and is categorized under NAICS code 622110 General Medical and Surgical Hospitals and PSC code R499 SUPPORT- PROFESSIONAL: OTHER.
This acquisition is a notice of intent to sole source and does not include a set-aside. The primary place of performance is Bethesda, Maryland. A single attachment titled Notice of Intent to Sole Source.pdf was published with the notice on May 19, 2026. Michael L. Falzone is the designated point of contact for this requirement, and the deadline for responses is June 3, 2026.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.